DK Life Science Co., Ltd. (KOSDAQ:303810)
2,225.00
+5.00 (0.23%)
Sep 14, 2026, 1:51 PM KST
DK Life Science Revenue
DK Life Science had revenue of 24.26B KRW in the quarter ending June 30, 2026, a decrease of -30.47%. This brings the company's revenue in the last twelve months to 117.75B, down -12.22% year-over-year. In the year 2025, DK Life Science had annual revenue of 130.34B, down -1.12%.
Revenue (ttm)
117.75B
Revenue Growth
-12.22%
P/S Ratio
0.60
Revenue / Employee
1.18B
Employees
100
Market Cap
71.00B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 130.34B | -1.47B | -1.12% |
| Dec 31, 2024 | 131.82B | 11.65B | 9.70% |
| Dec 31, 2023 | 120.16B | 12.93B | 12.05% |
| Dec 31, 2022 | 107.23B | 4.57B | 4.45% |
| Dec 31, 2021 | 102.67B | -6.91B | -6.31% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.12T |
| Celltrion | 4.90T |
| Samsung Epis Holdings | 1.51T |
| Ildong Holdings | 607.65B |
| ALTEOGEN | 254.01B |
| CKD Bio | 159.93B |
| DRTECH | 126.23B |
| Ray Co., Ltd. | 119.17B |